ViCentra B.V., with headquarters in Utrecht, the Netherlands develops, manufactures and markets next generation insulin pumps and other products to treat people with diabetes. The company flagship product is the Kaleido insulin pump which is CE marked and is commercially released in European countries. It is the world’s smallest and lightest insulin pump, waterproof, available in 10 bright colours and is available both as a manual and an automated insulin delivery system. ViCentra was founded in 2013 and is backed by INKEF Capital, EQT ventures, Health Innovations, Invest-NL, Partners in Equity and Kreos Capital. More information about ViCentra can be found at www.hellokaleido.com.

Non-executive Director & Chair of the Audit Committee. HealthBeacon, a medication adherence technology company, formerly trading on the Euronext Growth exchange, has developed the world’s first Injection Care Management System (ICMS) for patients that self-administer injectable medication in their homes. Worked with the Board and Management Team to navigate the Company through a period of significant change, leading to the sale of the Company in February 2024.

HVIVO plc (London and Euronext: ORPH) is a rapidly growing pharmaceutical service/contract research company that is a world leader in testing vaccines and antivirals using human challenge clinical trials. The Company provides services to Big Pharma, biotech and government/public health organisations. HVIVO Plc runs challenge studies in London from both its 19-bedroom Whitechapel quarantine clinic and its state-of-the-art 24-bedroom QMB clinic with its highly specialised on-site virology and immunology laboratory. HVIVO has a leading portfolio of human challenge study models for infectious and respiratory diseases and is developing a number of other models. There has been an explosion in the growth of the infectious disease pharmaceuticals market, which is estimated to grow to in excess of $250bn by 2025. The Group is focused on refreshing its existing challenge models and develop new models, such as Malaria, to address the dramatic growth potential of the global infectious disease market. HVIVO's Paris office has been providing biometry, data management and statistics to its many European pharmaceutical clients for over 20 years. For over 15 years, the Company's Netherlands office has been providing drug development consultancy and services, including CMC (chemistry, manufacturing and controls), PK and medical writing, to a broad range of European clients.

• Supported the merger and re-listing of Open Orphan plc with hVIVO plc in Jan 2020 creating a world leading CRO with expertise in Human Challenge Trials for infectious diseases and Early Clinical Development for drug compounds.• Appointed CFO of the merged entity, leading a 13-person team to cover all financial, accounting and legal matters. Supporting all aspects of Board governance and investor relations.• Led the restructuring of a non-performing clinical operations unit and the integration of corporate functions post-merger to return the business to profitability. • In 2020/2021, negotiated and led operational oversight of a contract (worth up to £40m) with the UK government to deliver a world first human challenge model for COVID-19. • Led the restructuring of the merged corporate structure to eliminate 60% of corporate entities, including the asset sale of a non core department. Implemented a new cross group accounting, planning & reporting system.• Supported the spin-out and IPO of Poolbeg Pharma plc in June 2021 which delivered a £25m dividend in specie to Open Orphan shareholders.• Contributed to deliver a record orderbook of c £80m in Aug 2022 to underpin strong growth expectations for FY 2022 & FY 2023• Delivered turnaround FY 2021 results: Revenue £39.0m (2020: £22.2m), EBITDA profit of £2.9m (2020: EBITDA loss of £6.1m)• Open Orphan share price (30th Jun 2022) up c 100% vs Jan 2020.

• Supported the reverse merger of Open Orphan DAC by Venn Life Licenses PLC on AIM in June 2019. Supporting corporate development projects in Open Orphan PLC.• Consulting for a Dublin based Strategy and Brand Consultancy. Projects cover strategic reviews for a publicly listed digital software player, a national energy utility and major supermarket brand.• Completed a financial review and commercial negotiation for a regional courier franchise group.• Completed seed equity financing of €2.0m in Feb 2019 and secured approval for government funding of €0.25m in July 2019 for VROMO Ltd, a technology start-up developing dispatch and marketing software for Last Mile Logistics.

In May 2018, completed a major fundraising event ($64 M) with three leading US/EU Healthcare funds (Orbimed, Longitude, HBM). As part of the Transaction, Sigmoid Pharma Limited was renamed as Sublimity Therapeutics Limited https://globenewswire.com/news-release/2018/05/22/1509805/0/en/Sublimity-Therapeutics-Closes-US-64-Million-Financing-to-Fund-Development-of-New-Oral-Ulcerative-Colitis-Drug-Candidate.htmlLed the restructuring of the Sigmoid group to prepare for Transaction, resulted in a successful approval by 90% (by value) of the existing c. 150 shareholders.

Sigmoid Pharma is a private pharma company headquartered in Dublin, Ireland. Utilising its proprietary SmPill® technology and known drugs, Sigmoid aims to be a global leader in the development of therapeutics to treat gastrointestinal (“GI”) diseases. • Raised €10 M in debt to fund operations. In Nov 2017, successfully managed the restructuring of €7 M of this debt due to the unexpected redemption call by a debt holder. • Completed the acquisition of Freund Pharmatec Ltd in Feb 2016 allowing the Company to secure clinical trial drug supply while adding a net €1 M in cash flow to the company.• Supported the completing of a major licence deal with Dr Falk Pharma – providing €4m in equity and valuable milestone payments. • Successfully managed the unexpected liquidation of a contract manufacturer to mitigate any liquidator claims and recover all Company assets. • Participated and played an active role in all Board meetings to oversee fundraising, cash management and operations.• Upgraded financial systems & processes for the Company, including full accounting month end processes and a detailed forecasting process for day to day business

Dec ‘13 to Date: ResMed Global Cardiology SBU- Promoted to report to Group CFO and become member of Finance Leadership Team- Working with the Cardiology Management Team to define a detailed investment plan ahead of anticipated 2015 clinical trial results for a ground breaking cardiology therapy- Supported the conclusion of a license agreement with a major global player to launch a new gaming platform using ResMed non-contact sensor technology Mar ‘13 to Nov ’13: ResMed Ventures & Initiatives (RVI)- Worked with RVI Management Team to define a 5 year plan for Cardiology and Consumer Businesses. Set Finance direction by driving clear business and financial objectives.- Secured funding for a new Consumer Device Strategy focusing on a consumer wellness device. - Successfully secured government grants worth €2 MJul ‘11 to Feb ’13: ResMed Sensor Technologies (RST) – formerly BiancaMed- Set a performance culture focusing on KPIs to deliver proactive monitoring and data based assessment of business performance. - Managed the commercial elements of a key contract manufacturer relationship including negotiating a final supply agreement.

BiancaMed is a World Leader in measuring respiration parameters using a novel Non Contact Sensor and Software PlatformIn July 2011, BiancaMed was acquired by Resmed Inc, a leading developer, manufacturer and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders.Key achievements were- Led the financial due diligence and legal process for the Jul 2011 acquisition by ResMed- Successfully completed company financing events in 2009 and 2011. Carried out related due diligence and legal requirements with new investors.- Supported CEO to manage ongoing Board relations including budget sign off meetings.- Led the Strategic Review Process for the Company in 2009/2010 allowing to focus on the high value Wellness & Medical partnering growth strategy- Upgraded all financial systems & processes for the Company, including full accounting month end processes and a detailed forecasting process for day to day business

Business Advisory Services

I have worked in a variety of Finance & Sales roles in Belgium, Switzerland & Ireland- Internal Audit- Financial Analysis- Financial Planning & Profit Forecasting- Customer Business Team Finance- Customer Business Development